iBio, Inc. Statistics
Total Valuation
iBio, Inc. has a market cap or net worth of $18.54 million. The enterprise value is $30.07 million.
| Market Cap | 18.54M |
| Enterprise Value | 30.07M |
Important Dates
The last earnings date was Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
iBio, Inc. has 8.62 million shares outstanding. The number of shares has increased by 463.43% in one year.
| Shares Outstanding | 8.62M |
| Shares Change (YoY) | +463.43% |
| Shares Change (QoQ) | +100.05% |
| Owned by Insiders (%) | 0.18% |
| Owned by Institutions (%) | 35.29% |
| Float | 6.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 370.82 |
| Forward PS | n/a |
| PB Ratio | 0.75 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 601.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.69, with a Debt / Equity ratio of 0.72.
| Current Ratio | 1.69 |
| Quick Ratio | n/a |
| Debt / Equity | 0.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -178.55 |
Financial Efficiency
Return on equity (ROE) is -147.90% and return on invested capital (ROIC) is -42.48%.
| Return on Equity (ROE) | -147.90% |
| Return on Assets (ROA) | -56.80% |
| Return on Capital (ROIC) | -42.48% |
| Revenue Per Employee | $1,923 |
| Profits Per Employee | -$890,846 |
| Employee Count | 26 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.46% in the last 52 weeks. The beta is -3.36, so iBio, Inc.'s price volatility has been lower than the market average.
| Beta (5Y) | -3.36 |
| 52-Week Price Change | -80.46% |
| 50-Day Moving Average | 2.18 |
| 200-Day Moving Average | 2.55 |
| Relative Strength Index (RSI) | 50.21 |
| Average Volume (20 Days) | 78,590 |
Short Selling Information
The latest short interest is 90,637, so 1.05% of the outstanding shares have been sold short.
| Short Interest | 90,637 |
| Short Previous Month | 95,460 |
| Short % of Shares Out | 1.05% |
| Short % of Float | 1.37% |
| Short Ratio (days to cover) | 0.57 |
Income Statement
In the last 12 months, iBio, Inc. had revenue of $50,000 and -$23.16 million in losses. Loss per share was -$4.87.
| Revenue | 50,000 |
| Gross Profit | 50,000 |
| Operating Income | -18.19M |
| Pretax Income | -23.16M |
| Net Income | -23.16M |
| EBITDA | -21.76M |
| EBIT | -23.03M |
| Loss Per Share | -$4.87 |
Balance Sheet
The company has $6.43 million in cash and $17.96 million in debt, giving a net cash position of -$11.53 million or -$1.34 per share.
| Cash & Cash Equivalents | 6.43M |
| Total Debt | 17.96M |
| Net Cash | -11.53M |
| Net Cash Per Share | -$1.34 |
| Equity (Book Value) | 24.86M |
| Book Value Per Share | 2.88 |
| Working Capital | 14.71M |
Cash Flow
In the last 12 months, operating cash flow was -$18.67 million and capital expenditures $1.04 million, giving a free cash flow of -$17.63 million.
| Operating Cash Flow | -18.67M |
| Capital Expenditures | 1.04M |
| Free Cash Flow | -17.63M |
| FCF Per Share | -$4.75 |
Margins
Gross margin is 100.00%, with operating and profit margins of -36,380.00% and -46,324.00%.
| Gross Margin | 100.00% |
| Operating Margin | -36,380.00% |
| Pretax Margin | -46,324.00% |
| Profit Margin | -46,324.00% |
| EBITDA Margin | -43,518.00% |
| EBIT Margin | -46,066.00% |
| FCF Margin | -35,252.00% |
Dividends & Yields
iBio, Inc. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -463.43% |
| Shareholder Yield | -463.43% |
| Earnings Yield | -124.92% |
| FCF Yield | -95.07% |
Analyst Forecast
The average price target for iBio, Inc. is $5.00, which is 132.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.00 |
| Price Target Difference | 132.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 29, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Nov 29, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
iBio, Inc. has an Altman Z-Score of -9.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.27 |
| Piotroski F-Score | 3 |